{"gene":"MGMT","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1990,"finding":"Human MGMT encodes a 22-kDa O6-methylguanine-DNA methyltransferase that repairs O6-alkylguanine adducts by stoichiometrically transferring the alkyl group to an active-site cysteine residue in a suicide reaction; the cDNA was cloned by functional rescue of an ada- E. coli host, and absence of MGMT expression in certain human cell lines was shown to result from absence of the gene or lack of its ~0.95-kb mRNA transcript.","method":"Functional complementation cloning in E. coli ada- mutant; in vitro methyltransferase activity assay; Northern blot analysis of MGMT mRNA","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of enzymatic activity in heterologous host plus biochemical characterization of active-site mechanism; foundational paper","pmids":["2405387"],"is_preprint":false},{"year":1993,"finding":"MGMT-mediated repair of O6-alkylguanine is a direct, single-step damage-reversal mechanism that inactivates the protein stoichiometrically (suicide enzyme), distinguishing it from catalytic repair enzymes; regulation of MGMT in mammalian cells involves both transcriptional control and post-translational protein stability.","method":"Biochemical assays of alkyltransferase activity; cell-based induction and depletion experiments reviewed with experimental data","journal":"Progress in nucleic acid research and molecular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzyme activity assays and genetic manipulations across multiple studies; well-replicated foundational mechanism","pmids":["8434121"],"is_preprint":false},{"year":1996,"finding":"Inactivated MGMT (after reaction with O6-benzylguanine or BCNU) is degraded via the ubiquitin-proteasome pathway: alkylated MGMT becomes polyubiquitinated within hours of inactivation, and proteolysis is ATP/Mg2+-dependent and blocked in a ts85 cell line carrying a thermolabile ubiquitin-activating enzyme.","method":"Co-immunoprecipitation and immunoblotting with anti-ubiquitin and anti-MGMT antibodies; anti-ubiquitin immunoaffinity chromatography; cell-free ubiquitination assay; temperature-sensitive ubiquitin-activating enzyme mutant cell line (ts85)","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal biochemical methods plus genetic validation with temperature-sensitive mutant; strong evidence for ubiquitin-mediated MGMT degradation","pmids":["8573590"],"is_preprint":false},{"year":2001,"finding":"O6-methylguanine induced by methylating agents is the major genotoxic and apoptotic lesion in MGMT-deficient cells; its cytotoxicity and apoptosis induction require functional mismatch repair (MMR), whereas N-alkylation damage repaired by BER becomes dominant when MGMT is highly expressed or when O6-methylguanine is scarce.","method":"Cell viability assays, apoptosis assays, and mutagenicity assays in cells with modulated MGMT and MMR activities; overexpression and antisense transfection experiments","journal":"Progress in nucleic acid research and molecular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis between MGMT and MMR pathway established across multiple experimental systems; well-replicated","pmids":["11554312"],"is_preprint":false},{"year":2003,"finding":"MGMT and MLH1 act in opposing pathways determining cell fate after alkylation damage: loss of MGMT sensitizes cells to MNU killing via MLH1-dependent apoptosis (caspase-3 induction), whereas additional Mlh1 deletion confers resistance and increases mutagenesis; MLH1 haploinsufficiency is sufficient to abolish apoptosis in Mgmt-/- cells, revealing a critical threshold for MMR-triggered cell death.","method":"Gene-targeted mouse cell lines (Mgmt-/-, Mlh1-/-, double knockout); cell survival assays; mutant frequency assays; caspase-3 immunoblotting; human MGMT cDNA overexpression","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1–2 — genetic epistasis established with isogenic knockout cell lines plus biochemical validation; strong evidence","pmids":["13679151"],"is_preprint":false},{"year":2004,"finding":"Human AGT/MGMT binds DNA through its helix-turn-helix (HTH) motif in the minor groove (an unprecedented mode for an HTH domain), flips the O6-methylguanine nucleotide out of the duplex via phosphate rotation assisted by Tyr114, and transfers the alkyl group to the active-site Cys145; crystal structures with O6-methylguanine-containing dsDNA and a crosslinked inhibitor N1,O6-ethanoxanthosine define the substrate-binding and catalytic mechanism.","method":"X-ray crystallography of human AGT/MGMT bound to dsDNA containing O6-methylguanine or crosslinked to mechanistic inhibitor; biochemical mutagenesis of Tyr114 and Cys145","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with substrate and inhibitor complexes plus mutagenesis; definitive mechanistic and structural study","pmids":["15221026"],"is_preprint":false},{"year":2007,"finding":"MGMT acts as a key cellular defense against O6-alkylating agents by directly reversing O6-methylguanine and O6-chloroethylguanine adducts; O6-methylguanine-induced clastogenicity and apoptosis require MutSα-dependent MMR and trigger the ATM/ATR–Chk1/Chk2–p53/p73 pathway with activation of both death receptor and mitochondrial apoptotic pathways, while O6-chloroethylguanine-induced killing is MMR-independent.","method":"MGMT-modulated cell lines (overexpression, knockdown, knockout); genotoxicity assays; apoptosis pathway analysis (caspase activation, cytochrome c release); epistasis with MMR-deficient lines","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 2 — extensive genetic epistasis experiments across multiple cell systems establishing pathway position; well-replicated across multiple labs cited within","pmids":["17485253"],"is_preprint":false},{"year":2010,"finding":"Levetiracetam (LEV) inhibits MGMT expression by enhancing p53 binding to the MGMT promoter and recruiting the mSin3A/HDAC1 corepressor complex; chromatin immunoprecipitation confirmed increased p53 occupancy at the MGMT promoter, and the MGMT-inhibitory effect was abolished by knockdown of p53, mSin3A, or HDAC1.","method":"Chromatin immunoprecipitation (ChIP); siRNA knockdown of p53, mSin3A, HDAC1; RT-PCR and western blot for MGMT mRNA and protein; patient biopsy samples pre- and post-LEV treatment","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and genetic knockdowns establish mechanism, but single-lab study with limited patient validation","pmids":["20525765"],"is_preprint":false},{"year":2013,"finding":"The mTOR target NDRG1 physically binds and stabilizes MGMT protein, protecting it from degradation; NDRG1 expression is induced by hypoxia (via HIF-1α), irradiation, corticosteroids, and chronic alkylating agent exposure through HIF-1α, p53, and mTORC2/SGK1 pathways, and NDRG1-dependent MGMT stabilization mediates resistance to alkylating chemotherapy but not radiotherapy.","method":"Co-immunoprecipitation of NDRG1 and MGMT; genetic knockdown/overexpression; glioma patient post-treatment tissue analysis; mouse xenograft models; pathway inhibitor experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP establishing direct interaction, multiple genetic perturbations, in vivo validation, and patient tissue confirmation","pmids":["24367102"],"is_preprint":false},{"year":2016,"finding":"MGMT undergoes post-translational regulation by ubiquitination (targeting inactivated protein for proteasomal degradation), sumoylation, and glutathionylation; the active-site Cys145 is exploited by thiol-reactive compounds (e.g., disulfiram, dithiocarbamate derivatives) to potently inactivate and deplete MGMT independent of the O6-benzylguanine pseudosubstrate strategy.","method":"Biochemical assays of MGMT ubiquitination, sumoylation, and glutathionylation; in vitro MGMT inactivation assays with thiol-reactive compounds; cell-based MGMT depletion assays","journal":"Mini reviews in medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 — biochemical characterization of PTMs reviewed from original experimental studies, but primarily a review synthesizing lab's own findings","pmids":["26202203"],"is_preprint":false},{"year":2018,"finding":"An enhancer element located between the MKI67 and MGMT gene promoters is activated in temozolomide-resistant glioblastoma; forced activation of this enhancer increases MGMT expression, while CRISPR-mediated deletion of the enhancer dramatically reduces MGMT and Ki67 expression, increases TMZ sensitivity, and impairs proliferation.","method":"CRISPR/dCas9-based enhancer activation; CRISPR deletion of enhancer; ChIP-seq; ATAC-seq; RNA-seq in patient-derived xenograft lines and recurrent tumor samples","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — gain- and loss-of-function genetic perturbations with multiple orthogonal genomic and functional assays; validated in PDX and clinical samples","pmids":["30054476"],"is_preprint":false},{"year":2018,"finding":"Fstl1 competes with DIP2A for binding, blocking DIP2A nuclear translocation; nuclear DIP2A normally associates with the HDAC2-DMAP1 complex to promote H3K9 deacetylation at the MGMT promoter, suppressing MGMT transcription. Fstl1 overexpression prevents this, increases H3K9 acetylation at the MGMT promoter, upregulates MGMT, and drives TMZ resistance; DIP2A depletion abolished the effects of Fstl1 on MGMT expression.","method":"Co-immunoprecipitation (Fstl1-DIP2A interaction); ChIP for H3K9Ac at MGMT promoter; siRNA knockdown and overexpression; nuclear fractionation; in vivo xenograft experiments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus ChIP plus genetic epistasis (DIP2A knockdown rescues Fstl1 effect) in vitro and in vivo","pmids":["30542120"],"is_preprint":false},{"year":2019,"finding":"MGMT transcriptionally activates DUB3, which in turn deubiquitinates and stabilizes MCL1 in ovarian cancer cells; the MGMT inhibitor PaTrin-2 suppresses this MGMT-DUB3-MCL1 axis and overcomes chemoresistance; HDAC inhibitors activate MGMT/DUB3 expression, and combined HDACi + PaTrin-2 is synergistic.","method":"Co-immunoprecipitation (DUB3-MCL1 interaction); ubiquitination assays; ChIP (MGMT binding at DUB3 promoter); siRNA knockdown; in vitro and in vivo tumor models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — direct biochemical interaction (Co-IP, ubiquitination assay), ChIP demonstrating MGMT at DUB3 promoter, genetic and pharmacological validation in vitro and in vivo","pmids":["30718431"],"is_preprint":false},{"year":2019,"finding":"HDAC8 regulates MGMT protein levels in glioblastoma through interaction with the proteasome receptor ADRM1; pharmacological inhibition or shRNA knockdown of HDAC8 decreases MGMT levels independent of MGMT promoter methylation status; TMZ treatment disrupts the HDAC8-ADRM1 interaction selectively in TMZ-sensitive cells, suggesting this pathway is inactivated in resistant cells.","method":"Co-immunoprecipitation (HDAC8-ADRM1); HDAC8-specific inhibitor (PCI34051) and shRNA knockdown; western blot for MGMT; cell viability and cell cycle assays; DNA damage marker (γH2AX)","journal":"Genes & cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP plus pharmacological and genetic perturbation; single-lab study with moderate mechanistic depth","pmids":["31798765"],"is_preprint":false},{"year":2019,"finding":"In MGMT-deficient tumor cells, temozolomide activates the ATR-Chk1 checkpoint axis in an MGMT-dependent manner; this sensitizes MGMT-deficient cells to ATR inhibitors both in vitro and in vivo, establishing functional crosstalk between MGMT-mediated repair and the ATR checkpoint pathway.","method":"Isogenic MGMT-proficient and MGMT-deficient cell lines; ATR inhibitor treatment; phospho-Chk1 immunoblotting; cell cycle analysis; in vivo xenograft experiments across multiple tumor types","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — isogenic cell line comparison with biochemical pathway readout, multiple tumor types, and in vivo validation","pmids":["31273061"],"is_preprint":false},{"year":2022,"finding":"PARP1 and MGMT interact directly in a DNA-independent manner; upon DNA alkylation damage, PARP1 also PARylates MGMT, forming a novel DNA damage-inducible PARP1-MGMT complex that enhances O6-methylguanine repair; this catalytic interaction reveals functional crosstalk between BER (PARP1) and direct repair (MGMT) pathways. Clinically relevant chronic TMZ exposure induced MGMT PARylation and increased PARP1-MGMT chromatin binding.","method":"Co-immunoprecipitation (PARP1-MGMT); in vitro PARylation assay; chromatin fractionation after TMZ treatment; MGMT repair activity assays comparing PARylated vs. unmodified MGMT","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 1–2 — direct protein-protein interaction (Co-IP), in vitro biochemical PARylation assay, and functional repair activity measurements with multiple orthogonal methods","pmids":["36242092"],"is_preprint":false},{"year":2022,"finding":"BET protein BRD4 binds the MGMT promoter and supports MGMT transcription; BET inhibitors reduce BRD4 and RNA Pol II occupancy at the MGMT promoter, attenuate MGMT expression (including TMZ-induced MGMT upregulation), and sensitize glioblastoma cells to TMZ; ectopic MGMT expression from an unrelated promoter rescues the effect, confirming specificity for MGMT transcriptional regulation.","method":"ChIP for BRD4 and Pol II at MGMT promoter; BET inhibitor treatment (JQ1 and others); ectopic MGMT overexpression rescue experiment; γH2AX measurement; MSH2/MSH6 expression monitoring; glioblastoma-derived sphere models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP establishes BRD4 occupancy at MGMT promoter, rescue experiment confirms mechanistic specificity, multiple functional readouts","pmids":["36513631"],"is_preprint":false},{"year":2022,"finding":"MSH2, MSH6, MLH1, and PMS2 (but not MSH3) are required for ATR pathway activation in response to TMZ in MGMT-promoter-methylated glioblastoma cells; isogenic MMR knockdown cell lines showed that these specific MMR proteins mediate the ATR-Chk1 signaling axis triggered by unrepaired O6-methylguanine.","method":"Isogenic shRNA knockdowns of individual MMR genes (MSH2, MSH6, MSH3, MLH1, PMS2) in MGMT-methylated glioblastoma cells; phospho-ATR and phospho-Chk1 immunoblotting after TMZ treatment","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — isogenic knockdown panel with defined biochemical readouts establishes pathway epistasis","pmids":["35388070"],"is_preprint":false},{"year":2023,"finding":"The small molecule EPIC-0412 epigenetically silences MGMT by disrupting binding of the ATF3-phospho-p65-HDAC1 complex at the MGMT promoter region, as demonstrated by ChIP and Co-IP assays; this reduces MGMT expression and sensitizes TMZ-resistant glioblastoma cells to temozolomide.","method":"Chromatin immunoprecipitation (ChIP) for ATF3, p-p65, HDAC1 at MGMT promoter; Co-immunoprecipitation of transcription factor complex; RNA immunoprecipitation (RIP); ChIRP; animal xenograft experiments","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and Co-IP demonstrate promoter-regulatory complex; single-lab study but multiple orthogonal methods","pmids":["36272139"],"is_preprint":false},{"year":2024,"finding":"In MGMT-promoter-methylated glioblastoma, TMZ activates CHK1, which phosphorylates the RNA helicase DDX46; phosphorylated DDX46 undergoes a conformational change increasing its helicase activity, which remodels the tertiary structure of lncRNA LINC01956 to expose binding motifs that recruit MGMT mRNA to the RNA nuclear export machinery, increasing cytoplasmic MGMT abundance and conferring TMZ resistance; CHK1 inhibition abolishes this structural remodeling and resensitizes cells to TMZ.","method":"RNA immunoprecipitation (RIP); ChIRP; mass spectrometry; structural probing assays (SHAPE/DMS-MaPseq) of LINC01956; phosphoproteomic analysis of DDX46; CHK1 inhibitor (SRA737) treatment; patient-derived xenograft and tumor organoid models","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1–2 — RNA structural probing, RIP, ChIRP, phosphoproteomics, and PDX/organoid validation with pharmacological rescue; multiple orthogonal methods in a single rigorous study","pmids":["39356744"],"is_preprint":false}],"current_model":"MGMT (O6-methylguanine-DNA methyltransferase) is a suicide DNA repair enzyme that directly transfers alkyl groups from O6-alkylguanine adducts to its active-site Cys145 via a nucleotide-flipping mechanism involving minor-groove HTH binding and Tyr114-assisted phosphate rotation, after which the alkylated protein is degraded by the ubiquitin-proteasome pathway; MGMT expression is regulated at multiple levels including BRD4-dependent transcription, an MKI67-proximal enhancer, p53/mSin3A/HDAC1-mediated promoter repression, Fstl1/DIP2A/HDAC2 chromatin acetylation control, and post-transcriptional nuclear export of MGMT mRNA via CHK1-DDX46-LINC01956 remodeling, while at the protein level NDRG1 stabilizes MGMT and PARP1 PARylates MGMT to enhance O6-methylguanine repair through BER-MGMT pathway crosstalk; when MGMT is absent, unrepaired O6-methylguanine triggers MSH2/MSH6/MLH1/PMS2-dependent ATR-Chk1 checkpoint activation and ultimately MMR-dependent apoptosis via ATM/ATR-p53/p73 signaling."},"narrative":{"teleology":[{"year":1990,"claim":"Cloning of human MGMT established that O6-alkylguanine repair proceeds through a suicide mechanism in which the enzyme irreversibly transfers the alkyl group to an active-site cysteine, explaining the stoichiometric depletion of repair capacity in mammalian cells.","evidence":"Functional complementation cloning in E. coli ada− mutant with in vitro methyltransferase activity assay and Northern blot","pmids":["2405387"],"confidence":"High","gaps":["Active-site cysteine not yet identified by mutagenesis","No structural information on substrate recognition","Post-translational fate of alkylated protein unknown"]},{"year":1996,"claim":"The question of how inactivated MGMT is cleared was resolved by showing that alkylated MGMT is polyubiquitinated and degraded via the ATP-dependent proteasome pathway, establishing a complete single-use repair cycle.","evidence":"Co-IP with anti-ubiquitin antibodies, cell-free ubiquitination assay, and temperature-sensitive ubiquitin-activating enzyme mutant (ts85 cells)","pmids":["8573590"],"confidence":"High","gaps":["E3 ligase responsible for MGMT ubiquitination not identified","Whether sumoylation or other PTMs modulate degradation kinetics"]},{"year":2001,"claim":"Genetic epistasis experiments answered why MGMT loss is cytotoxic: unrepaired O6-methylguanine is processed by mismatch repair into a lethal signal, establishing the MGMT–MMR functional opposition that underlies alkylating-agent sensitivity.","evidence":"Cell viability and apoptosis assays in cells with modulated MGMT and MMR status; antisense and overexpression experiments","pmids":["11554312","13679151"],"confidence":"High","gaps":["Exact nature of the MMR-generated lethal intermediate (futile cycling vs. strand break) not resolved","Whether MMR-independent killing occurs for specific adduct types"]},{"year":2004,"claim":"Crystal structures of MGMT bound to O6-methylguanine-containing DNA revealed the catalytic mechanism: minor-groove HTH binding, Tyr114-driven phosphate rotation to flip the damaged base, and direct alkyl transfer to Cys145, answering how a single protein accomplishes lesion recognition and repair in one step.","evidence":"X-ray crystallography of human MGMT–dsDNA complexes with substrate and crosslinked inhibitor; site-directed mutagenesis of Tyr114 and Cys145","pmids":["15221026"],"confidence":"High","gaps":["Dynamics of nucleotide flipping in solution not captured by crystal structures","Structural basis for cooperative binding to DNA not fully resolved"]},{"year":2007,"claim":"The downstream signaling cascade following MGMT deficiency was mapped: unrepaired O6-methylguanine activates ATM/ATR–Chk1/Chk2–p53/p73 through MutSα-dependent MMR, engaging both death-receptor and mitochondrial apoptotic pathways, while O6-chloroethylguanine killing was shown to be MMR-independent.","evidence":"MGMT-modulated cell lines with epistasis across MMR-deficient lines; caspase activation and cytochrome c release assays","pmids":["17485253"],"confidence":"High","gaps":["Relative contribution of p53 vs. p73 in different cell types unclear","Whether ATR-Chk1 signaling is the sole checkpoint engaged"]},{"year":2013,"claim":"NDRG1 was identified as a direct binding partner that stabilizes MGMT protein, revealing a post-translational mechanism by which the hypoxia–mTORC2–SGK1 axis sustains alkylating-agent resistance independently of MGMT transcription.","evidence":"Reciprocal Co-IP of NDRG1–MGMT; genetic knockdown/overexpression; glioma patient tissue and mouse xenograft validation","pmids":["24367102"],"confidence":"High","gaps":["Structural basis of NDRG1–MGMT interaction unknown","Whether NDRG1 shields specific ubiquitination sites not determined"]},{"year":2018,"claim":"Multi-layered transcriptional regulation of MGMT was established: a distal enhancer between MKI67 and MGMT drives resistance-associated upregulation, while the Fstl1/DIP2A/HDAC2-DMAP1 axis controls H3K9 acetylation at the MGMT promoter, answering how MGMT expression is reactivated in resistant tumors despite promoter methylation.","evidence":"CRISPR enhancer deletion and dCas9 activation with ATAC-seq/ChIP-seq (enhancer study); Co-IP plus ChIP for H3K9Ac and epistasis with DIP2A knockdown (Fstl1 study); PDX models","pmids":["30054476","30542120"],"confidence":"High","gaps":["Transcription factors binding the MKI67-proximal enhancer not fully catalogued","Whether enhancer activation is specific to recurrent GBM or a general mechanism"]},{"year":2019,"claim":"The checkpoint consequence of MGMT loss was refined: ATR-Chk1 activation by temozolomide requires MSH2, MSH6, MLH1, and PMS2 but not MSH3, delineating the specific MMR components that transduce unrepaired O6-methylguanine into checkpoint signaling and revealing ATR inhibitor vulnerability in MGMT-deficient tumors.","evidence":"Isogenic shRNA knockdown panel of individual MMR genes in MGMT-methylated GBM cells; phospho-ATR/Chk1 immunoblotting; ATR inhibitor treatment in vitro and in xenografts","pmids":["31273061","35388070"],"confidence":"High","gaps":["Whether ATR inhibitor sensitivity extends to all MGMT-deficient tumor types","Role of secondary MMR-independent checkpoint pathways not excluded"]},{"year":2022,"claim":"BRD4 was shown to occupy the MGMT promoter and sustain Pol II–driven transcription, and PARP1 was found to PARylate MGMT in a DNA-independent manner enhancing its repair activity, revealing two previously unrecognized regulatory nodes—one transcriptional, one post-translational—that converge on MGMT output.","evidence":"ChIP for BRD4/Pol II with BET-inhibitor treatment and ectopic MGMT rescue (transcription); reciprocal Co-IP of PARP1–MGMT and in vitro PARylation plus repair activity assay (PTM)","pmids":["36513631","36242092"],"confidence":"High","gaps":["Which PARylation sites on MGMT are functionally relevant not mapped","Whether BRD4-dependent transcription operates at the distal enhancer as well as the core promoter"]},{"year":2024,"claim":"A post-transcriptional resistance mechanism was uncovered: CHK1 phosphorylates DDX46, whose increased helicase activity remodels lncRNA LINC01956 to expose motifs that recruit MGMT mRNA for nuclear export, explaining how cytoplasmic MGMT protein rises during alkylation stress even in promoter-methylated tumors.","evidence":"RNA structural probing (SHAPE/DMS-MaPseq), RIP, ChIRP, phosphoproteomics of DDX46, CHK1 inhibitor rescue in PDX and tumor organoid models","pmids":["39356744"],"confidence":"High","gaps":["Whether LINC01956-mediated export applies to non-glioblastoma contexts","Identity of the nuclear export receptor that recognizes remodeled LINC01956","Whether other RNA helicases can substitute for DDX46"]},{"year":null,"claim":"Key unresolved questions include the identity of the E3 ubiquitin ligase(s) targeting alkylated MGMT for degradation, the structural basis of the NDRG1–MGMT and PARP1–MGMT interactions, and whether the transcriptional activator function of MGMT at the DUB3 promoter represents a widespread non-canonical role or a context-specific phenomenon.","evidence":"","pmids":[],"confidence":"Low","gaps":["E3 ligase for MGMT ubiquitination remains unidentified","No co-crystal structure of MGMT with any of its regulatory partners","Non-canonical transcription factor activity of MGMT at DUB3 awaits independent replication"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,15,19]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,1,3,5,6,15]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[3,4,6,14,17]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[7,10,11,16]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[19]}],"complexes":[],"partners":["NDRG1","PARP1","BRD4","DDX46","DIP2A","HDAC8","ADRM1","TP53"],"other_free_text":[]},"mechanistic_narrative":"MGMT is a suicide DNA repair enzyme that directly reverses O6-alkylguanine lesions by stoichiometrically transferring the alkyl group to its active-site Cys145, after which the inactivated protein is polyubiquitinated and degraded by the proteasome [PMID:2405387, PMID:8573590]. Structural studies reveal that MGMT binds the DNA minor groove through a helix-turn-helix motif, flips the damaged nucleotide out of the duplex via Tyr114-assisted phosphate rotation, and executes methyl transfer at Cys145 [PMID:15221026]. MGMT transcription is controlled by BRD4-dependent promoter activity, a distal MKI67-proximal enhancer, p53/mSin3A/HDAC1-mediated repression, and Fstl1/DIP2A/HDAC2-regulated chromatin acetylation, while post-translationally NDRG1 stabilizes MGMT protein and PARP1 PARylates MGMT to enhance repair through BER–direct-repair crosstalk [PMID:36513631, PMID:30054476, PMID:20525765, PMID:30542120, PMID:24367102, PMID:36242092]. When MGMT is absent, unrepaired O6-methylguanine triggers MSH2/MSH6/MLH1/PMS2-dependent ATR-Chk1 checkpoint activation and apoptosis via ATM/ATR–p53/p73 signaling, and MGMT mRNA export is further enhanced under alkylation stress through CHK1-dependent DDX46 phosphorylation and LINC01956 structural remodeling [PMID:35388070, PMID:17485253, PMID:39356744]."},"prefetch_data":{"uniprot":{"accession":"P16455","full_name":"Methylated-DNA--protein-cysteine methyltransferase","aliases":["6-O-methylguanine-DNA methyltransferase","MGMT","O-6-methylguanine-DNA-alkyltransferase"],"length_aa":207,"mass_kda":21.6,"function":"Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P16455/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MGMT","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MGMT","total_profiled":1310},"omim":[{"mim_id":"615826","title":"SPERM-TAIL PG-RICH REPEAT-CONTAINING PROTEIN 1; STPG1","url":"https://www.omim.org/entry/615826"},{"mim_id":"609941","title":"DEAFNESS, AUTOSOMAL RECESSIVE 51; DFNB51","url":"https://www.omim.org/entry/609941"},{"mim_id":"300329","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 33; ZBTB33","url":"https://www.omim.org/entry/300329"},{"mim_id":"156569","title":"METHYLGUANINE-DNA METHYLTRANSFERASE; MGMT","url":"https://www.omim.org/entry/156569"},{"mim_id":"137800","title":"GLIOMA SUSCEPTIBILITY 1; GLM1","url":"https://www.omim.org/entry/137800"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":125.9}],"url":"https://www.proteinatlas.org/search/MGMT"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P16455","domains":[{"cath_id":"3.30.160.70","chopping":"2-86","consensus_level":"medium","plddt":88.0181,"start":2,"end":86},{"cath_id":"1.10.10.10","chopping":"88-183","consensus_level":"medium","plddt":94.8295,"start":88,"end":183}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16455","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16455-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16455-F1-predicted_aligned_error_v6.png","plddt_mean":85.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MGMT","jax_strain_url":"https://www.jax.org/strain/search?query=MGMT"},"sequence":{"accession":"P16455","fasta_url":"https://rest.uniprot.org/uniprotkb/P16455.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16455/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16455"}},"corpus_meta":[{"pmid":"15758010","id":"PMC_15758010","title":"MGMT gene silencing and benefit from temozolomide in glioblastoma.","date":"2005","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15758010","citation_count":5676,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18757334","id":"PMC_18757334","title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18757334","citation_count":681,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17485253","id":"PMC_17485253","title":"MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17485253","citation_count":504,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16174854","id":"PMC_16174854","title":"MGMT promoter methylation and field defect in sporadic colorectal cancer.","date":"2005","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/16174854","citation_count":390,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11981013","id":"PMC_11981013","title":"Clinical relevance of MGMT in the treatment of cancer.","date":"2002","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11981013","citation_count":362,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18952979","id":"PMC_18952979","title":"Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.","date":"2008","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18952979","citation_count":318,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20309962","id":"PMC_20309962","title":"Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20309962","citation_count":247,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30054476","id":"PMC_30054476","title":"A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30054476","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32010632","id":"PMC_32010632","title":"O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32010632","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16428468","id":"PMC_16428468","title":"Targeted modulation of MGMT: clinical implications.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16428468","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24367102","id":"PMC_24367102","title":"mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24367102","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20525765","id":"PMC_20525765","title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20525765","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26503470","id":"PMC_26503470","title":"IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26503470","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24109190","id":"PMC_24109190","title":"Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.","date":"2013","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24109190","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20517307","id":"PMC_20517307","title":"Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.","date":"2010","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20517307","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18091318","id":"PMC_18091318","title":"MGMT immunohistochemical expression and promoter methylation in human glioblastoma.","date":"2008","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/18091318","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18997474","id":"PMC_18997474","title":"Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.","date":"2008","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/18997474","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24147153","id":"PMC_24147153","title":"MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24147153","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22701311","id":"PMC_22701311","title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.","date":"2012","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/22701311","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11554312","id":"PMC_11554312","title":"BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis.","date":"2001","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11554312","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20179017","id":"PMC_20179017","title":"MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20179017","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16094446","id":"PMC_16094446","title":"Epigenetic silencing of the MGMT gene in cancer.","date":"2005","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/16094446","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30718431","id":"PMC_30718431","title":"MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30718431","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23958055","id":"PMC_23958055","title":"Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.","date":"2013","source":"Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23958055","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21097691","id":"PMC_21097691","title":"Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21097691","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28353639","id":"PMC_28353639","title":"Influence of MTHFR Genetic Background on p16 and MGMT Methylation in Oral Squamous Cell Cancer.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28353639","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22214427","id":"PMC_22214427","title":"Volumetric and MGMT parameters in glioblastoma patients: survival analysis.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22214427","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16777483","id":"PMC_16777483","title":"Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.","date":"2006","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16777483","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12483540","id":"PMC_12483540","title":"Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12483540","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31766430","id":"PMC_31766430","title":"Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31766430","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22672670","id":"PMC_22672670","title":"MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22672670","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31273061","id":"PMC_31273061","title":"Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31273061","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18473722","id":"PMC_18473722","title":"Role of mismatch repair and MGMT in response to anticancer therapies.","date":"2008","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18473722","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36272139","id":"PMC_36272139","title":"A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.","date":"2023","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36272139","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25394859","id":"PMC_25394859","title":"Treatment considerations for MGMT-unmethylated glioblastoma.","date":"2015","source":"Current neurology and neuroscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/25394859","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29016808","id":"PMC_29016808","title":"Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.","date":"2018","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29016808","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30542120","id":"PMC_30542120","title":"Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30542120","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21311951","id":"PMC_21311951","title":"MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.","date":"2011","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21311951","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20740317","id":"PMC_20740317","title":"MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.","date":"2010","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/20740317","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37451151","id":"PMC_37451151","title":"Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37451151","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33460245","id":"PMC_33460245","title":"Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.","date":"2021","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33460245","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"13679151","id":"PMC_13679151","title":"Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis.","date":"2003","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/13679151","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31413318","id":"PMC_31413318","title":"Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.","date":"2019","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31413318","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21329652","id":"PMC_21329652","title":"A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21329652","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21708177","id":"PMC_21708177","title":"O(6)-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke.","date":"2011","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/21708177","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17569599","id":"PMC_17569599","title":"Genetic association and functional studies of major polymorphic variants of MGMT.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17569599","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32007918","id":"PMC_32007918","title":"Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32007918","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30549269","id":"PMC_30549269","title":"Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.","date":"2019","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30549269","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23716983","id":"PMC_23716983","title":"MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults.","date":"2013","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23716983","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22228432","id":"PMC_22228432","title":"Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.","date":"2012","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/22228432","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31798765","id":"PMC_31798765","title":"HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.","date":"2019","source":"Genes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31798765","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38242327","id":"PMC_38242327","title":"MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives.","date":"2024","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/38242327","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28314386","id":"PMC_28314386","title":"Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.","date":"2017","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28314386","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21274674","id":"PMC_21274674","title":"Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21274674","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11802813","id":"PMC_11802813","title":"O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.","date":"2002","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/11802813","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19544111","id":"PMC_19544111","title":"Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.","date":"2009","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19544111","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30824408","id":"PMC_30824408","title":"O6-methylguanine-DNA methyltransferase (MGMT) status in neuroendocrine tumors: a randomized phase II study (MGMT-NET).","date":"2019","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/30824408","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22788764","id":"PMC_22788764","title":"Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.","date":"2012","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22788764","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32354046","id":"PMC_32354046","title":"The Role of miRNA for the Treatment of MGMT Unmethylated Glioblastoma Multiforme.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32354046","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21822153","id":"PMC_21822153","title":"O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.","date":"2012","source":"Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/21822153","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25516857","id":"PMC_25516857","title":"Role of MGMT as biomarker in colorectal cancer.","date":"2014","source":"World journal of clinical cases","url":"https://pubmed.ncbi.nlm.nih.gov/25516857","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31740551","id":"PMC_31740551","title":"Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31740551","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38277015","id":"PMC_38277015","title":"Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.","date":"2024","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38277015","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26202203","id":"PMC_26202203","title":"Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.","date":"2016","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26202203","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19892775","id":"PMC_19892775","title":"Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis.","date":"2009","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19892775","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28848211","id":"PMC_28848211","title":"Association Between MGMT Promoter Methylation and Breast Cancer: a Meta-Analysis.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28848211","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31865606","id":"PMC_31865606","title":"IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.","date":"2019","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/31865606","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37524206","id":"PMC_37524206","title":"Modulating MGMT expression through interfering with cell signaling pathways.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37524206","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37634280","id":"PMC_37634280","title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma.","date":"2023","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37634280","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28001451","id":"PMC_28001451","title":"MGMT hypomethylation is associated with DNA damage in workers exposed to low-dose benzene.","date":"2017","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/28001451","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24397721","id":"PMC_24397721","title":"Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.","date":"2014","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/24397721","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22609488","id":"PMC_22609488","title":"Progress in high-throughput assays of MGMT and APE1 activities in cell extracts.","date":"2012","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/22609488","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17569600","id":"PMC_17569600","title":"Lung cancer risk and variation in MGMT activity and sequence.","date":"2007","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/17569600","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36513631","id":"PMC_36513631","title":"BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36513631","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26379107","id":"PMC_26379107","title":"Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.","date":"2015","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/26379107","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33209885","id":"PMC_33209885","title":"Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression.","date":"2020","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33209885","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36242092","id":"PMC_36242092","title":"PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair.","date":"2022","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36242092","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27492578","id":"PMC_27492578","title":"O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?","date":"2016","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/27492578","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30444735","id":"PMC_30444735","title":"MGMT Testing in Glioblastomas: Pitfalls and Opportunities.","date":"2019","source":"American journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30444735","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32698158","id":"PMC_32698158","title":"Critical appraisal of MGMT in digestive NET treated with alkylating agents.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32698158","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35388070","id":"PMC_35388070","title":"Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35388070","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30673883","id":"PMC_30673883","title":"Predictive markers for MGMT promoter methylation in glioblastomas.","date":"2019","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/30673883","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18973931","id":"PMC_18973931","title":"Absence of MGMT promoter methylation in endometrial cancer.","date":"2008","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18973931","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33041828","id":"PMC_33041828","title":"Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33041828","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24938706","id":"PMC_24938706","title":"Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer.","date":"2014","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24938706","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29801405","id":"PMC_29801405","title":"O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.","date":"2018","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/29801405","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31264147","id":"PMC_31264147","title":"Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.","date":"2019","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/31264147","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2233795","id":"PMC_2233795","title":"The control of O6-methylguanine-DNA methyltransferase (MGMT) activity in mammalian cells: a pre-molecular view.","date":"1990","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/2233795","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27657735","id":"PMC_27657735","title":"Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27657735","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16607377","id":"PMC_16607377","title":"hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16607377","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34016221","id":"PMC_34016221","title":"Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms.","date":"2021","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/34016221","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31058280","id":"PMC_31058280","title":"Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.","date":"2019","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31058280","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24151575","id":"PMC_24151575","title":"Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24151575","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39356744","id":"PMC_39356744","title":"Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT-methylated glioblastoma.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39356744","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34976195","id":"PMC_34976195","title":"Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation.","date":"2022","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34976195","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36261081","id":"PMC_36261081","title":"Organochlorine pesticides may induce leukemia by methylation of CDKN2B and MGMT promoters and histone modifications.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/36261081","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30677446","id":"PMC_30677446","title":"Germline variation in O6-methylguanine-DNA methyltransferase (MGMT) as cause of hereditary colorectal cancer.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30677446","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28436299","id":"PMC_28436299","title":"MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.","date":"2017","source":"Journal of chemotherapy (Florence, Italy)","url":"https://pubmed.ncbi.nlm.nih.gov/28436299","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30038102","id":"PMC_30038102","title":"MGMT gene promoter methylation and its correlation with clinicopathological parameters in glioblastomas.","date":"2018","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/30038102","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30194078","id":"PMC_30194078","title":"Pyrosequencing Analysis of MGMT Promoter Methylation in Meningioma.","date":"2018","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/30194078","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15765097","id":"PMC_15765097","title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15765097","citation_count":1390,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25163906","id":"PMC_25163906","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.","date":"2014","source":"The Lancet. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25163906","citation_count":854,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18445844","id":"PMC_18445844","title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18445844","citation_count":663,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15041700","id":"PMC_15041700","title":"Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/15041700","citation_count":662,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19805672","id":"PMC_19805672","title":"Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19805672","citation_count":490,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20150378","id":"PMC_20150378","title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.","date":"2009","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20150378","citation_count":338,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16195237","id":"PMC_16195237","title":"Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.","date":"2005","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16195237","citation_count":333,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2405387","id":"PMC_2405387","title":"Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2405387","citation_count":298,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16203797","id":"PMC_16203797","title":"Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16203797","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22810491","id":"PMC_22810491","title":"MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.","date":"2012","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/22810491","citation_count":267,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15221026","id":"PMC_15221026","title":"DNA binding and nucleotide flipping by the human DNA repair protein AGT.","date":"2004","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15221026","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21425258","id":"PMC_21425258","title":"Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.","date":"2011","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21425258","citation_count":254,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32348734","id":"PMC_32348734","title":"MGMT Status as a Clinical Biomarker in Glioblastoma.","date":"2020","source":"Trends in cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32348734","citation_count":253,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22322613","id":"PMC_22322613","title":"Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.","date":"2012","source":"AJNR. American journal of neuroradiology","url":"https://pubmed.ncbi.nlm.nih.gov/22322613","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28266716","id":"PMC_28266716","title":"The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28266716","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15455350","id":"PMC_15455350","title":"Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.","date":"2005","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15455350","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18509181","id":"PMC_18509181","title":"Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.","date":"2008","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18509181","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22139906","id":"PMC_22139906","title":"Predictive impact of MGMT promoter methylation in glioblastoma of the elderly.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22139906","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16609022","id":"PMC_16609022","title":"Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16609022","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19901104","id":"PMC_19901104","title":"MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19901104","citation_count":205,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18516290","id":"PMC_18516290","title":"PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18516290","citation_count":204,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27503138","id":"PMC_27503138","title":"A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.","date":"2016","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/27503138","citation_count":199,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8573590","id":"PMC_8573590","title":"Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea.","date":"1996","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8573590","citation_count":192,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24068788","id":"PMC_24068788","title":"Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24068788","citation_count":190,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18400046","id":"PMC_18400046","title":"Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.","date":"2008","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/18400046","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8434121","id":"PMC_8434121","title":"Regulation of repair of alkylation damage in mammalian genomes.","date":"1993","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8434121","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53258,"output_tokens":5470,"usd":0.120912},"stage2":{"model":"claude-opus-4-6","input_tokens":9040,"output_tokens":3460,"usd":0.19755},"total_usd":0.665366,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":69984,"output_tokens":6373,"usd":0.152774},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9634,"output_tokens":3250,"usd":0.19413}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"MGMT (O6-methylguanine-DNA methyltransferase) functions as a suicide enzyme that directly removes alkyl groups from the O6-position of guanine in DNA, transferring the alkyl group to a cysteine residue in its active site (Cys145), thereby becoming irreversibly inactivated in a single-step catalytic mechanism without requiring other repair proteins.\",\n      \"method\": \"In vitro enzymatic assay, active-site mutagenesis, biochemical characterization\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mechanistic detail (suicide enzyme, alkyl transfer to Cys145) established by multiple orthogonal biochemical studies, replicated across labs over decades; described as established mechanism in multiple review papers in corpus\",\n      \"pmids\": [\"17485253\", \"11554312\", \"18473722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"O6-methylguanine (O6-MeG) lesions, when not repaired by MGMT, require MutSalpha-dependent mismatch repair (MMR) to trigger clastogenicity and cell death; in MGMT-deficient cells, O6-MeG-induced apoptosis proceeds via ATM/ATR, Chk1, Chk2, p53, and p73 signaling after formation of secondary DNA double-strand breaks.\",\n      \"method\": \"Genetic epistasis using MGMT-/- and MLH1-/- knockout mouse cell lines, cell survival assays, caspase-3 induction measurement\",\n      \"journal\": \"Progress in nucleic acid research and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO cell lines with defined cellular phenotype, epistasis confirmed in multiple papers using complementary approaches\",\n      \"pmids\": [\"11554312\", \"13679151\", \"17485253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MGMT loss sensitizes cells to alkylating agent (MNU)-induced apoptosis via a caspase-3-dependent pathway; this cell death requires functional MLH1 mismatch repair protein, and Mlh1 haploinsufficiency is sufficient to confer resistance to killing comparable to full Mlh1 knockout in Mgmt-deficient cells.\",\n      \"method\": \"Gene-targeted knockout mouse cell lines (Mgmt-/-, Mlh1-/-, compound mutants), caspase-3 induction assay, cell survival assay, mutagenesis frequency measurement\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean genetic knockout with defined mechanistic phenotype, multiple genotypes tested with orthogonal readouts\",\n      \"pmids\": [\"13679151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NDRG1, an mTOR target induced by hypoxia, binds to and stabilizes MGMT protein, thereby protecting it from degradation and contributing to alkylating agent resistance; this interaction was identified in glioblastoma cells and post-treatment tumor tissue.\",\n      \"method\": \"Co-immunoprecipitation, western blot, loss-of-function (siRNA/shRNA), post-treatment tumor tissue analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP identifying binding partner with functional consequence (drug resistance), single lab\",\n      \"pmids\": [\"24367102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP1 directly interacts with MGMT in a non-catalytic (DNA-independent) manner and also PARylates MGMT after DNA damage, forming a novel DNA damage-inducible PARP1-MGMT complex; PARylation of MGMT enhances O6-methylguanine repair, revealing functional crosstalk between base excision repair and MGMT-mediated repair.\",\n      \"method\": \"Co-immunoprecipitation, in vitro PARylation assay, chromatin binding assay, functional O6meG repair assay, temozolomide treatment experiments\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct interaction shown by Co-IP with functional consequence (enhanced repair), multiple orthogonal methods in single lab\",\n      \"pmids\": [\"36242092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Levetiracetam decreases MGMT expression by enhancing p53 binding at the MGMT promoter through recruitment of the mSin3A/HDAC1 corepressor complex; this effect is abrogated when p53, mSin3A, or HDAC1 expression is knocked down.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), siRNA knockdown, western blot, RT-PCR, patient biopsy validation\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with mechanistic follow-up using knockdown of pathway components, validated in patient samples\",\n      \"pmids\": [\"20525765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Fstl1 competitively binds DIP2A to block its nuclear translocation, preventing DIP2A from associating with the HDAC2-DMAP1 complex; this complex normally deacetylates H3K9Ac at the MGMT promoter to suppress MGMT transcription, so Fstl1 overexpression increases H3K9Ac and MGMT expression, promoting temozolomide resistance.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation, siRNA knockdown, overexpression, in vivo xenograft model, western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches including Co-IP, ChIP, and in vivo validation in single lab\",\n      \"pmids\": [\"30542120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MGMT activates DUB3 transcription; DUB3 in turn interacts with and deubiquitinates MCL1 in the cytoplasm of ovarian cancer cells, protecting MCL1 from proteasomal degradation and promoting chemoresistance.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assay, western blot, in vitro and in vivo functional assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying MGMT as transcriptional activator of DUB3 with functional cascade validated in vitro and in vivo, single lab\",\n      \"pmids\": [\"30718431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MiR-221 and miR-222 directly target MGMT mRNA, reducing MGMT protein expression; overexpression of MGMT rescues the increased DNA damage markers induced by miR-221 overexpression in glioma cells.\",\n      \"method\": \"Luciferase reporter assay (implied), western blot, overexpression rescue experiment, DNA damage marker quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — target validation with rescue experiment, single lab\",\n      \"pmids\": [\"24147153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC8 regulates MGMT protein levels in glioblastoma cells via interaction with the proteasome receptor ADRM1; inhibition of HDAC8 decreases MGMT levels independently of MGMT promoter methylation status, and TMZ treatment disrupts the HDAC8-ADRM1 interaction specifically in TMZ-sensitive cells.\",\n      \"method\": \"HDAC8-specific inhibitor (PCI34051), HDAC8 shRNA knockdown, Co-immunoprecipitation, western blot, cell viability assay\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP with functional knockdown validation, promoter methylation-independent mechanism confirmed, single lab\",\n      \"pmids\": [\"31798765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Temozolomide activates the ATR-Chk1 signaling axis in MGMT-deficient tumor cells, inducing G2-M cell cycle arrest and DNA double-strand breaks; this sensitization to ATR inhibitors is highly dependent on reduced MGMT expression and occurs across multiple tumor cell types in vitro and in vivo.\",\n      \"method\": \"MGMT-deficient vs. MGMT-proficient isogenic cell lines, ATR inhibitor combination treatment, flow cytometry (cell cycle), γH2AX assay, in vivo xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic comparison with defined pathway (ATR-Chk1) activation, multiple cell types and in vivo validation\",\n      \"pmids\": [\"31273061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mismatch repair proteins MSH2, MSH6, MLH1, and PMS2 (but not MSH3) are required for ATR axis activation after temozolomide exposure in MGMT-promoter-methylated glioblastoma cells; isogenic MMR knockdown cell lines demonstrate that MMR mediates ATR-Chk1 signaling downstream of O6-methylguanine lesions.\",\n      \"method\": \"Isogenic cell lines with individual MMR gene knockdowns (shRNA), ATR/Chk1 phosphorylation assays, western blot\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean isogenic knockdowns with defined signaling pathway readout, multiple MMR proteins tested\",\n      \"pmids\": [\"35388070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"An enhancer element located between the MKI67 and MGMT gene promoters is activated in temozolomide-resistant glioblastoma; forced activation of this enhancer increases MGMT expression, and deletion of the enhancer reduces MGMT expression and restores temozolomide sensitivity.\",\n      \"method\": \"CRISPR-based enhancer activation/deletion, ChIP-seq, RNA-seq, patient-derived xenograft models, cell viability assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — CRISPR gain-of-function and loss-of-function with functional validation in PDX models, multiple orthogonal methods\",\n      \"pmids\": [\"30054476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RIP2 promotes MGMT expression and temozolomide resistance by activating the NF-κB signaling pathway, which transcriptionally upregulates MGMT; RIP2 silencing reduces MGMT expression and sensitizes glioma cells to TMZ in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, plasmid overexpression, western blot, immunofluorescence, xenograft model, NF-κB inhibitor (JSH-23) treatment\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement via knockdown/overexpression with in vivo validation, single lab\",\n      \"pmids\": [\"33460245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In MGMT-promoter-methylated glioblastoma, TMZ-activated CHK1 phosphorylates DDX46, increasing its helicase activity; DDX46 then remodels the tertiary structure of lncRNA LINC01956, exposing binding motifs that recruit MGMT mRNA to the RNA export machinery and increase MGMT abundance in the cytoplasm, driving TMZ resistance.\",\n      \"method\": \"RNA immunoprecipitation (RIP), ChIRP, CHK1 inhibitor (SRA737), patient-derived xenograft models, tumor organoid models, structural RNA analysis\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal molecular methods (RIP, ChIRP) with PDX/organoid validation, single lab\",\n      \"pmids\": [\"39356744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MGMT protein stability and DNA repair activity are regulated by post-translational modifications including ubiquitination, sumoylation, and glutathionylation; the active-site cysteine (Cys145) can be targeted by thiol-reacting drugs such as disulfiram and dithiocarbamate derivatives to inactivate and deplete MGMT.\",\n      \"method\": \"In vitro modification assays, active-site mutagenesis, biochemical characterization of PTMs\",\n      \"journal\": \"Mini reviews in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-3 — PTMs described based on laboratory work with active-site functional validation, single lab review of their own work\",\n      \"pmids\": [\"26202203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Bortezomib (proteasome inhibitor) pre-treatment depletes MGMT mRNA and protein in glioblastoma cells with unmethylated MGMT promoter by reducing NFkB/p65 processing to its active form without affecting MGMT promoter methylation, thereby sensitizing cells to temozolomide.\",\n      \"method\": \"Western blot, qRT-PCR, pyrosequencing (methylation), proteasome activity assay, LC-MS/MS (drug biodistribution), orthotopic xenograft mouse model\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including in vivo validation; mechanism linked to NF-κB processing\",\n      \"pmids\": [\"31413318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BET protein inhibitors (BETi) attenuate MGMT expression in glioblastoma cells by reducing BRD4 and RNA Polymerase II binding at the MGMT promoter; BETi also inhibit TMZ-induced MGMT upregulation, and ectopic MGMT expression under an unrelated promoter is not affected, confirming the mechanism is promoter-specific.\",\n      \"method\": \"ChIP-seq (BRD4, Pol II), ectopic MGMT expression rescue, γH2AX assay, BET inhibitor treatment, GBM-derived sphere cultures\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq with mechanistic rescue experiment confirming promoter-specific regulation, multiple orthogonal methods\",\n      \"pmids\": [\"36513631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MGMT inhibitors (O6-benzylguanine and O6-(4-bromothenyl)guanine) and their glucose conjugates are subject to active efflux by ABC transporters (P-glycoprotein, MRP1, BCRP), which reduces intracellular drug levels and limits MGMT inhibition; pharmacological inhibition of efflux transporters restores sensitivity.\",\n      \"method\": \"Cell-based uptake/efflux assays, specific ABC transporter inhibitors, cell death/MGMT activity assays in multiple cell lines\",\n      \"journal\": \"Molecular pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic efflux identified with functional consequence on MGMT inhibition, multiple transporter inhibitors tested\",\n      \"pmids\": [\"26379107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Epigenetic silencing of MGMT by promoter CpG island methylation suppresses MGMT expression and DNA repair activity; this is associated with a non-permissive chromatin state, and the degree of promoter methylation correlates with MGMT transcript levels and enzyme activity.\",\n      \"method\": \"Methylation-specific PCR, bisulfite sequencing, chromatin immunoprecipitation (chromatin status), MGMT activity assay, RT-PCR\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods linking methylation to chromatin state to gene expression to enzyme activity, replicated across many labs\",\n      \"pmids\": [\"16094446\", \"21097691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EPIC-0412 epigenetically silences MGMT through interaction with the ATF3-p-p65-HDAC1 axis at the MGMT promoter region; Co-immunoprecipitation revealed interactions among these transcription factors at the MGMT promoter, and ChIP confirmed EPIC-0412-mediated changes in occupancy.\",\n      \"method\": \"RNA immunoprecipitation (RIP), ChIRP, chromatin immunoprecipitation (ChIP), Co-immunoprecipitation, in vivo mouse model\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal molecular methods identifying transcriptional complex at MGMT promoter with in vivo validation\",\n      \"pmids\": [\"36272139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GBM cells exhibit intrinsic circadian rhythms in MGMT expression and promoter methylation; TMZ sensitivity peaks at the daily maximum of Bmal1 transcription, which corresponds to minimum MGMT activity; inhibition of MGMT with O6-benzylguanine abolishes the daily rhythm in TMZ sensitivity.\",\n      \"method\": \"Real-time bioluminescence reporters (circadian clock genes), RT-PCR (MGMT transcript), bisulfite pyrosequencing (MGMT methylation), O6-BG pharmacological inhibition, in vivo xenograft timing experiment\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking circadian MGMT regulation to functional TMZ sensitivity, in vivo validation\",\n      \"pmids\": [\"38277015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Increased MGMT expression (by transfection) decreases sensitivity to camptothecin (CPT) derivatives including irinotecan (CPT-11), SN-38, and DX-8951f; conversely, antisense-mediated MGMT repression sensitizes cells; TMZ treatment causes dose-dependent decreases in both MGMT and topoisomerase I in MGMT-expressing cells, suggesting MGMT participates in topoisomerase I-mediated DNA damage/repair processes.\",\n      \"method\": \"MGMT sense/antisense transfection, drug sensitivity assays (17 cell lines), O6-BG MGMT inhibition, western blot\",\n      \"journal\": \"Japanese journal of cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — transfection-based gain/loss of function with correlation; mechanistic link to topoisomerase I remains inferential\",\n      \"pmids\": [\"11802813\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MGMT is a suicide DNA repair enzyme that directly and irreversibly transfers alkyl groups from the O6-position of guanine to its active-site Cys145 residue, providing the primary cellular defense against cytotoxic O6-alkylguanine adducts induced by alkylating agents; its activity is regulated at multiple levels including epigenetic promoter methylation (which silences expression via a non-permissive chromatin state), transcriptional control by NF-κB, p53/HDAC1, BRD4, and enhancer elements, post-translational modifications (ubiquitination, sumoylation, glutathionylation, PARylation by PARP1), and protein stabilization by NDRG1, while unrepaired O6-methylguanine lesions activate MMR-dependent ATR-Chk1 signaling and ultimately apoptosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract mechanistic discoveries only from KEEP papers.\n\n**Classification summary:**\n- Most papers are about MGMT (O6-methylguanine-DNA methyltransferase) — KEEP\n- Papers about general epigenetics, MGC cDNA collections, histone modifications unrelated to MGMT, phosphoproteomics screens, GO annotation, DNA repair gene polymorphisms without MGMT mechanism — EXCLUDE if no MGMT mechanistic content\n- Key KEEP papers with mechanistic content: PMID 2405387 (cDNA cloning, suicide mechanism), PMID 15221026 (structure/DNA binding), PMID 8573590 (ubiquitination), PMID 17485253 (mechanism review with experimental basis), PMID 11554312 (BER/MMR/MGMT roles), PMID 13679151 (Mgmt/Mlh1 epistasis), PMID 24367102 (NDRG1 stabilizes MGMT), PMID 30718431 (MGMT-DUB3-MCL1 axis), PMID 36242092 (PARP1-MGMT complex), PMID 30054476 (enhancer regulates MGMT), PMID 20525765 (p53/mSin3A/HDAC1 represses MGMT), PMID 37524206 (signaling pathway regulation), PMID 24151575, PMID 31273061 (TMZ/ATR/MGMT), PMID 30542120 (Fstl1/DIP2A/MGMT), PMID 31798765 (HDAC8/ADRM1/MGMT), PMID 36513631 (BET/BRD4/MGMT), PMID 8434121 (regulation review), PMID 26202203 (PTM review), PMID 36272139 (EPIC-0412/ATF3 axis), PMID 39356744 (LINC01956/DDX46/MGMT mRNA export)\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"Human MGMT encodes a 22-kDa O6-methylguanine-DNA methyltransferase that repairs O6-alkylguanine adducts by stoichiometrically transferring the alkyl group to an active-site cysteine residue in a suicide reaction; the cDNA was cloned by functional rescue of an ada- E. coli host, and absence of MGMT expression in certain human cell lines was shown to result from absence of the gene or lack of its ~0.95-kb mRNA transcript.\",\n      \"method\": \"Functional complementation cloning in E. coli ada- mutant; in vitro methyltransferase activity assay; Northern blot analysis of MGMT mRNA\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of enzymatic activity in heterologous host plus biochemical characterization of active-site mechanism; foundational paper\",\n      \"pmids\": [\"2405387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"MGMT-mediated repair of O6-alkylguanine is a direct, single-step damage-reversal mechanism that inactivates the protein stoichiometrically (suicide enzyme), distinguishing it from catalytic repair enzymes; regulation of MGMT in mammalian cells involves both transcriptional control and post-translational protein stability.\",\n      \"method\": \"Biochemical assays of alkyltransferase activity; cell-based induction and depletion experiments reviewed with experimental data\",\n      \"journal\": \"Progress in nucleic acid research and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzyme activity assays and genetic manipulations across multiple studies; well-replicated foundational mechanism\",\n      \"pmids\": [\"8434121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Inactivated MGMT (after reaction with O6-benzylguanine or BCNU) is degraded via the ubiquitin-proteasome pathway: alkylated MGMT becomes polyubiquitinated within hours of inactivation, and proteolysis is ATP/Mg2+-dependent and blocked in a ts85 cell line carrying a thermolabile ubiquitin-activating enzyme.\",\n      \"method\": \"Co-immunoprecipitation and immunoblotting with anti-ubiquitin and anti-MGMT antibodies; anti-ubiquitin immunoaffinity chromatography; cell-free ubiquitination assay; temperature-sensitive ubiquitin-activating enzyme mutant cell line (ts85)\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal biochemical methods plus genetic validation with temperature-sensitive mutant; strong evidence for ubiquitin-mediated MGMT degradation\",\n      \"pmids\": [\"8573590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"O6-methylguanine induced by methylating agents is the major genotoxic and apoptotic lesion in MGMT-deficient cells; its cytotoxicity and apoptosis induction require functional mismatch repair (MMR), whereas N-alkylation damage repaired by BER becomes dominant when MGMT is highly expressed or when O6-methylguanine is scarce.\",\n      \"method\": \"Cell viability assays, apoptosis assays, and mutagenicity assays in cells with modulated MGMT and MMR activities; overexpression and antisense transfection experiments\",\n      \"journal\": \"Progress in nucleic acid research and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis between MGMT and MMR pathway established across multiple experimental systems; well-replicated\",\n      \"pmids\": [\"11554312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MGMT and MLH1 act in opposing pathways determining cell fate after alkylation damage: loss of MGMT sensitizes cells to MNU killing via MLH1-dependent apoptosis (caspase-3 induction), whereas additional Mlh1 deletion confers resistance and increases mutagenesis; MLH1 haploinsufficiency is sufficient to abolish apoptosis in Mgmt-/- cells, revealing a critical threshold for MMR-triggered cell death.\",\n      \"method\": \"Gene-targeted mouse cell lines (Mgmt-/-, Mlh1-/-, double knockout); cell survival assays; mutant frequency assays; caspase-3 immunoblotting; human MGMT cDNA overexpression\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genetic epistasis established with isogenic knockout cell lines plus biochemical validation; strong evidence\",\n      \"pmids\": [\"13679151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human AGT/MGMT binds DNA through its helix-turn-helix (HTH) motif in the minor groove (an unprecedented mode for an HTH domain), flips the O6-methylguanine nucleotide out of the duplex via phosphate rotation assisted by Tyr114, and transfers the alkyl group to the active-site Cys145; crystal structures with O6-methylguanine-containing dsDNA and a crosslinked inhibitor N1,O6-ethanoxanthosine define the substrate-binding and catalytic mechanism.\",\n      \"method\": \"X-ray crystallography of human AGT/MGMT bound to dsDNA containing O6-methylguanine or crosslinked to mechanistic inhibitor; biochemical mutagenesis of Tyr114 and Cys145\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with substrate and inhibitor complexes plus mutagenesis; definitive mechanistic and structural study\",\n      \"pmids\": [\"15221026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MGMT acts as a key cellular defense against O6-alkylating agents by directly reversing O6-methylguanine and O6-chloroethylguanine adducts; O6-methylguanine-induced clastogenicity and apoptosis require MutSα-dependent MMR and trigger the ATM/ATR–Chk1/Chk2–p53/p73 pathway with activation of both death receptor and mitochondrial apoptotic pathways, while O6-chloroethylguanine-induced killing is MMR-independent.\",\n      \"method\": \"MGMT-modulated cell lines (overexpression, knockdown, knockout); genotoxicity assays; apoptosis pathway analysis (caspase activation, cytochrome c release); epistasis with MMR-deficient lines\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — extensive genetic epistasis experiments across multiple cell systems establishing pathway position; well-replicated across multiple labs cited within\",\n      \"pmids\": [\"17485253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Levetiracetam (LEV) inhibits MGMT expression by enhancing p53 binding to the MGMT promoter and recruiting the mSin3A/HDAC1 corepressor complex; chromatin immunoprecipitation confirmed increased p53 occupancy at the MGMT promoter, and the MGMT-inhibitory effect was abolished by knockdown of p53, mSin3A, or HDAC1.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); siRNA knockdown of p53, mSin3A, HDAC1; RT-PCR and western blot for MGMT mRNA and protein; patient biopsy samples pre- and post-LEV treatment\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and genetic knockdowns establish mechanism, but single-lab study with limited patient validation\",\n      \"pmids\": [\"20525765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The mTOR target NDRG1 physically binds and stabilizes MGMT protein, protecting it from degradation; NDRG1 expression is induced by hypoxia (via HIF-1α), irradiation, corticosteroids, and chronic alkylating agent exposure through HIF-1α, p53, and mTORC2/SGK1 pathways, and NDRG1-dependent MGMT stabilization mediates resistance to alkylating chemotherapy but not radiotherapy.\",\n      \"method\": \"Co-immunoprecipitation of NDRG1 and MGMT; genetic knockdown/overexpression; glioma patient post-treatment tissue analysis; mouse xenograft models; pathway inhibitor experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP establishing direct interaction, multiple genetic perturbations, in vivo validation, and patient tissue confirmation\",\n      \"pmids\": [\"24367102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MGMT undergoes post-translational regulation by ubiquitination (targeting inactivated protein for proteasomal degradation), sumoylation, and glutathionylation; the active-site Cys145 is exploited by thiol-reactive compounds (e.g., disulfiram, dithiocarbamate derivatives) to potently inactivate and deplete MGMT independent of the O6-benzylguanine pseudosubstrate strategy.\",\n      \"method\": \"Biochemical assays of MGMT ubiquitination, sumoylation, and glutathionylation; in vitro MGMT inactivation assays with thiol-reactive compounds; cell-based MGMT depletion assays\",\n      \"journal\": \"Mini reviews in medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — biochemical characterization of PTMs reviewed from original experimental studies, but primarily a review synthesizing lab's own findings\",\n      \"pmids\": [\"26202203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"An enhancer element located between the MKI67 and MGMT gene promoters is activated in temozolomide-resistant glioblastoma; forced activation of this enhancer increases MGMT expression, while CRISPR-mediated deletion of the enhancer dramatically reduces MGMT and Ki67 expression, increases TMZ sensitivity, and impairs proliferation.\",\n      \"method\": \"CRISPR/dCas9-based enhancer activation; CRISPR deletion of enhancer; ChIP-seq; ATAC-seq; RNA-seq in patient-derived xenograft lines and recurrent tumor samples\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — gain- and loss-of-function genetic perturbations with multiple orthogonal genomic and functional assays; validated in PDX and clinical samples\",\n      \"pmids\": [\"30054476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Fstl1 competes with DIP2A for binding, blocking DIP2A nuclear translocation; nuclear DIP2A normally associates with the HDAC2-DMAP1 complex to promote H3K9 deacetylation at the MGMT promoter, suppressing MGMT transcription. Fstl1 overexpression prevents this, increases H3K9 acetylation at the MGMT promoter, upregulates MGMT, and drives TMZ resistance; DIP2A depletion abolished the effects of Fstl1 on MGMT expression.\",\n      \"method\": \"Co-immunoprecipitation (Fstl1-DIP2A interaction); ChIP for H3K9Ac at MGMT promoter; siRNA knockdown and overexpression; nuclear fractionation; in vivo xenograft experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus ChIP plus genetic epistasis (DIP2A knockdown rescues Fstl1 effect) in vitro and in vivo\",\n      \"pmids\": [\"30542120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MGMT transcriptionally activates DUB3, which in turn deubiquitinates and stabilizes MCL1 in ovarian cancer cells; the MGMT inhibitor PaTrin-2 suppresses this MGMT-DUB3-MCL1 axis and overcomes chemoresistance; HDAC inhibitors activate MGMT/DUB3 expression, and combined HDACi + PaTrin-2 is synergistic.\",\n      \"method\": \"Co-immunoprecipitation (DUB3-MCL1 interaction); ubiquitination assays; ChIP (MGMT binding at DUB3 promoter); siRNA knockdown; in vitro and in vivo tumor models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct biochemical interaction (Co-IP, ubiquitination assay), ChIP demonstrating MGMT at DUB3 promoter, genetic and pharmacological validation in vitro and in vivo\",\n      \"pmids\": [\"30718431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"HDAC8 regulates MGMT protein levels in glioblastoma through interaction with the proteasome receptor ADRM1; pharmacological inhibition or shRNA knockdown of HDAC8 decreases MGMT levels independent of MGMT promoter methylation status; TMZ treatment disrupts the HDAC8-ADRM1 interaction selectively in TMZ-sensitive cells, suggesting this pathway is inactivated in resistant cells.\",\n      \"method\": \"Co-immunoprecipitation (HDAC8-ADRM1); HDAC8-specific inhibitor (PCI34051) and shRNA knockdown; western blot for MGMT; cell viability and cell cycle assays; DNA damage marker (γH2AX)\",\n      \"journal\": \"Genes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP plus pharmacological and genetic perturbation; single-lab study with moderate mechanistic depth\",\n      \"pmids\": [\"31798765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In MGMT-deficient tumor cells, temozolomide activates the ATR-Chk1 checkpoint axis in an MGMT-dependent manner; this sensitizes MGMT-deficient cells to ATR inhibitors both in vitro and in vivo, establishing functional crosstalk between MGMT-mediated repair and the ATR checkpoint pathway.\",\n      \"method\": \"Isogenic MGMT-proficient and MGMT-deficient cell lines; ATR inhibitor treatment; phospho-Chk1 immunoblotting; cell cycle analysis; in vivo xenograft experiments across multiple tumor types\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic cell line comparison with biochemical pathway readout, multiple tumor types, and in vivo validation\",\n      \"pmids\": [\"31273061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PARP1 and MGMT interact directly in a DNA-independent manner; upon DNA alkylation damage, PARP1 also PARylates MGMT, forming a novel DNA damage-inducible PARP1-MGMT complex that enhances O6-methylguanine repair; this catalytic interaction reveals functional crosstalk between BER (PARP1) and direct repair (MGMT) pathways. Clinically relevant chronic TMZ exposure induced MGMT PARylation and increased PARP1-MGMT chromatin binding.\",\n      \"method\": \"Co-immunoprecipitation (PARP1-MGMT); in vitro PARylation assay; chromatin fractionation after TMZ treatment; MGMT repair activity assays comparing PARylated vs. unmodified MGMT\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct protein-protein interaction (Co-IP), in vitro biochemical PARylation assay, and functional repair activity measurements with multiple orthogonal methods\",\n      \"pmids\": [\"36242092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BET protein BRD4 binds the MGMT promoter and supports MGMT transcription; BET inhibitors reduce BRD4 and RNA Pol II occupancy at the MGMT promoter, attenuate MGMT expression (including TMZ-induced MGMT upregulation), and sensitize glioblastoma cells to TMZ; ectopic MGMT expression from an unrelated promoter rescues the effect, confirming specificity for MGMT transcriptional regulation.\",\n      \"method\": \"ChIP for BRD4 and Pol II at MGMT promoter; BET inhibitor treatment (JQ1 and others); ectopic MGMT overexpression rescue experiment; γH2AX measurement; MSH2/MSH6 expression monitoring; glioblastoma-derived sphere models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP establishes BRD4 occupancy at MGMT promoter, rescue experiment confirms mechanistic specificity, multiple functional readouts\",\n      \"pmids\": [\"36513631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MSH2, MSH6, MLH1, and PMS2 (but not MSH3) are required for ATR pathway activation in response to TMZ in MGMT-promoter-methylated glioblastoma cells; isogenic MMR knockdown cell lines showed that these specific MMR proteins mediate the ATR-Chk1 signaling axis triggered by unrepaired O6-methylguanine.\",\n      \"method\": \"Isogenic shRNA knockdowns of individual MMR genes (MSH2, MSH6, MSH3, MLH1, PMS2) in MGMT-methylated glioblastoma cells; phospho-ATR and phospho-Chk1 immunoblotting after TMZ treatment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic knockdown panel with defined biochemical readouts establishes pathway epistasis\",\n      \"pmids\": [\"35388070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The small molecule EPIC-0412 epigenetically silences MGMT by disrupting binding of the ATF3-phospho-p65-HDAC1 complex at the MGMT promoter region, as demonstrated by ChIP and Co-IP assays; this reduces MGMT expression and sensitizes TMZ-resistant glioblastoma cells to temozolomide.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for ATF3, p-p65, HDAC1 at MGMT promoter; Co-immunoprecipitation of transcription factor complex; RNA immunoprecipitation (RIP); ChIRP; animal xenograft experiments\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and Co-IP demonstrate promoter-regulatory complex; single-lab study but multiple orthogonal methods\",\n      \"pmids\": [\"36272139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In MGMT-promoter-methylated glioblastoma, TMZ activates CHK1, which phosphorylates the RNA helicase DDX46; phosphorylated DDX46 undergoes a conformational change increasing its helicase activity, which remodels the tertiary structure of lncRNA LINC01956 to expose binding motifs that recruit MGMT mRNA to the RNA nuclear export machinery, increasing cytoplasmic MGMT abundance and conferring TMZ resistance; CHK1 inhibition abolishes this structural remodeling and resensitizes cells to TMZ.\",\n      \"method\": \"RNA immunoprecipitation (RIP); ChIRP; mass spectrometry; structural probing assays (SHAPE/DMS-MaPseq) of LINC01956; phosphoproteomic analysis of DDX46; CHK1 inhibitor (SRA737) treatment; patient-derived xenograft and tumor organoid models\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — RNA structural probing, RIP, ChIRP, phosphoproteomics, and PDX/organoid validation with pharmacological rescue; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"39356744\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MGMT (O6-methylguanine-DNA methyltransferase) is a suicide DNA repair enzyme that directly transfers alkyl groups from O6-alkylguanine adducts to its active-site Cys145 via a nucleotide-flipping mechanism involving minor-groove HTH binding and Tyr114-assisted phosphate rotation, after which the alkylated protein is degraded by the ubiquitin-proteasome pathway; MGMT expression is regulated at multiple levels including BRD4-dependent transcription, an MKI67-proximal enhancer, p53/mSin3A/HDAC1-mediated promoter repression, Fstl1/DIP2A/HDAC2 chromatin acetylation control, and post-transcriptional nuclear export of MGMT mRNA via CHK1-DDX46-LINC01956 remodeling, while at the protein level NDRG1 stabilizes MGMT and PARP1 PARylates MGMT to enhance O6-methylguanine repair through BER-MGMT pathway crosstalk; when MGMT is absent, unrepaired O6-methylguanine triggers MSH2/MSH6/MLH1/PMS2-dependent ATR-Chk1 checkpoint activation and ultimately MMR-dependent apoptosis via ATM/ATR-p53/p73 signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MGMT is a suicide DNA repair enzyme that serves as the primary cellular defense against mutagenic and cytotoxic O6-alkylguanine lesions by directly and irreversibly transferring alkyl groups from the O6-position of guanine to its active-site Cys145 residue, consuming itself stoichiometrically in each repair event [PMID:17485253, PMID:11554312]. When MGMT is absent or silenced—most commonly by CpG island promoter methylation that establishes a non-permissive chromatin state—unrepaired O6-methylguanine lesions are recognized by MutSα-dependent mismatch repair (requiring MSH2, MSH6, MLH1, and PMS2), triggering ATR-Chk1 signaling, G2-M arrest, and caspase-3-dependent apoptosis [PMID:13679151, PMID:31273061, PMID:35388070]. MGMT expression is regulated at multiple levels: transcriptionally by NF-κB, p53/HDAC1, BRD4, enhancer elements, and circadian Bmal1 rhythms [PMID:30054476, PMID:33460245, PMID:36513631, PMID:38277015]; post-transcriptionally by miR-221/222 and lncRNA LINC01956-mediated mRNA export [PMID:24147153, PMID:39356744]; and post-translationally by ubiquitination, sumoylation, glutathionylation, PARylation by PARP1, and NDRG1-mediated protein stabilization [PMID:26202203, PMID:36242092, PMID:24367102]. Beyond its canonical DNA repair role, MGMT transcriptionally activates DUB3, which deubiquitinates and stabilizes the anti-apoptotic protein MCL1, contributing to chemoresistance independently of direct alkyl-damage repair [PMID:30718431].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing the core enzymatic mechanism resolved how cells directly reverse O6-alkylguanine damage: MGMT acts as a single-use suicide enzyme transferring the alkyl group to Cys145, requiring no cofactors or partner proteins.\",\n      \"evidence\": \"In vitro enzymatic assays with active-site mutagenesis across multiple labs over decades, consolidated in reviews\",\n      \"pmids\": [\"17485253\", \"11554312\", \"18473722\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full structural dynamics of the alkyl-transfer transition state in a human MGMT–DNA co-crystal\", \"Whether MGMT has any catalytic activity beyond O6-alkylguanine repair remains uncertain\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining the downstream death pathway showed that unrepaired O6-MeG lesions are not intrinsically cytotoxic but require MMR-dependent processing to generate lethal secondary lesions, establishing the MGMT-MMR epistasis that governs alkylating agent sensitivity.\",\n      \"evidence\": \"Genetic epistasis in Mgmt−/−, Mlh1−/−, and compound knockout mouse cell lines with caspase-3 induction and cell survival readouts\",\n      \"pmids\": [\"13679151\", \"11554312\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise nature of the secondary DNA lesion (replication fork collapse vs. futile cycling) not fully resolved\", \"Relative contributions of ATM vs. ATR in different cell types unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linking promoter CpG methylation to a non-permissive chromatin state and loss of MGMT enzyme activity explained why epigenetic silencing, rather than mutation, is the predominant mechanism of MGMT inactivation in tumors.\",\n      \"evidence\": \"Methylation-specific PCR, bisulfite sequencing, ChIP for chromatin marks, correlated with MGMT transcript and activity levels across multiple labs\",\n      \"pmids\": [\"16094446\", \"21097691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals that initiate de novo MGMT promoter methylation remain unknown\", \"Whether methylation is uniform across CpG sites or follows a hierarchical pattern is debated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying p53/mSin3A/HDAC1 recruitment to the MGMT promoter revealed that MGMT transcription is actively repressed by a specific corepressor complex, expanding the regulatory landscape beyond promoter methylation.\",\n      \"evidence\": \"ChIP showing p53 and HDAC1 occupancy at MGMT promoter, abrogated by siRNA knockdown of each component, in glioblastoma cells treated with levetiracetam\",\n      \"pmids\": [\"20525765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether p53/HDAC1 repression operates independently of promoter methylation status needs clarification\", \"Drug-specific vs. physiological relevance of this regulatory axis not distinguished\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that NDRG1 binds and stabilizes MGMT protein introduced post-translational protein stabilization as a distinct regulatory tier for MGMT activity, linking hypoxia/mTOR signaling to DNA repair capacity.\",\n      \"evidence\": \"Co-immunoprecipitation and siRNA/shRNA in glioblastoma cells and post-treatment tumor tissue\",\n      \"pmids\": [\"24367102\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the NDRG1–MGMT interaction unknown\", \"Whether NDRG1 protects MGMT from ubiquitin-dependent or ubiquitin-independent degradation not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Cataloguing post-translational modifications (ubiquitination, sumoylation, glutathionylation) of MGMT—including targeting of the active-site Cys145 by thiol-reactive compounds—showed that MGMT is regulated by multiple PTMs beyond simple protein turnover.\",\n      \"evidence\": \"In vitro modification assays and active-site mutagenesis with functional readouts\",\n      \"pmids\": [\"26202203\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific E3 ligases and SUMO ligases responsible not identified\", \"Relative physiological importance of each PTM in vivo unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CRISPR-based activation and deletion of an enhancer between MKI67 and MGMT demonstrated that distal cis-regulatory elements control MGMT expression and TMZ resistance independently of promoter methylation, adding an enhancer-level regulatory dimension.\",\n      \"evidence\": \"CRISPR enhancer activation/deletion, ChIP-seq, RNA-seq, patient-derived xenograft models\",\n      \"pmids\": [\"30054476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors binding this enhancer not fully characterized\", \"Whether the enhancer is active in non-GBM tumor types not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple studies converged to show that NF-κB pathway activation (via RIP2 or p65 processing) transcriptionally upregulates MGMT, and that BRD4 occupancy at the MGMT promoter is required for its expression, defining two additional druggable transcriptional nodes.\",\n      \"evidence\": \"siRNA/overexpression of RIP2 with NF-κB inhibitor validation plus xenograft models; bortezomib reducing p65 processing; ChIP-seq for BRD4/Pol II with ectopic MGMT rescue\",\n      \"pmids\": [\"33460245\", \"31413318\", \"36513631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NF-κB and BRD4 act on the same or distinct promoter elements not resolved\", \"Relative contribution of each pathway in vivo under physiological conditions unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that TMZ activates ATR-Chk1 specifically in MGMT-deficient cells across multiple tumor types, with MMR components MSH2/MSH6/MLH1/PMS2 required for this signaling, precisely defined the molecular pathway linking O6-MeG persistence to checkpoint activation and therapeutic vulnerability.\",\n      \"evidence\": \"Isogenic MGMT-proficient vs. -deficient cell lines, individual MMR gene knockdowns, ATR/Chk1 phosphorylation readouts, in vivo xenograft models\",\n      \"pmids\": [\"31273061\", \"35388070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATR-Chk1 activation is sufficient for cell death or requires additional downstream effectors not fully delineated\", \"Role of MSH3 exclusion in this specific pathway not mechanistically explained\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying a non-canonical transcriptional role for MGMT—activating DUB3, which deubiquitinates MCL1 to confer chemoresistance—extended MGMT function beyond direct DNA repair to anti-apoptotic signaling.\",\n      \"evidence\": \"Transcriptional reporter assay, Co-IP of DUB3-MCL1, in vitro and in vivo functional assays in ovarian cancer cells\",\n      \"pmids\": [\"30718431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MGMT activates DUB3 transcription (direct DNA binding vs. cofactor recruitment) not established\", \"Whether this function operates in cell types beyond ovarian cancer unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that PARP1 both constitutively interacts with MGMT and PARylates it upon DNA damage, with PARylation enhancing O6-MeG repair, established functional crosstalk between BER-associated PARP1 and direct damage reversal.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro PARylation assay, chromatin binding assay, functional O6-MeG repair assay after TMZ treatment\",\n      \"pmids\": [\"36242092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PARylation sites on MGMT not mapped\", \"Whether PARP inhibitors clinically affect MGMT repair activity not tested\", \"Independent replication needed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linking circadian Bmal1 rhythms to daily oscillations in MGMT expression, promoter methylation, and TMZ sensitivity revealed that MGMT-mediated repair capacity is under chronobiological control.\",\n      \"evidence\": \"Real-time bioluminescence circadian reporters, RT-PCR, bisulfite pyrosequencing, O6-BG abolishment of rhythm, in vivo xenograft timing experiment\",\n      \"pmids\": [\"38277015\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking BMAL1 to MGMT promoter methylation dynamics not identified\", \"Clinical applicability of chronotherapy based on MGMT rhythms not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: the structural basis for MGMT's diverse protein–protein interactions (NDRG1, PARP1), the identity of the E3 ubiquitin ligase(s) targeting MGMT for degradation, and whether MGMT's non-canonical transcriptional functions generalize beyond specific tumor contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No E3 ligase for MGMT ubiquitination identified\", \"No high-resolution structure of MGMT in complex with any binding partner\", \"Non-canonical transcriptional roles tested only in single cancer types\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4, 19]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 2, 4, 10, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 2, 10]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [5, 6, 19, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 10, 11, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 13, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PARP1\",\n      \"NDRG1\",\n      \"HDAC1\",\n      \"BRD4\",\n      \"MSH2\",\n      \"MSH6\",\n      \"MLH1\",\n      \"HDAC8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MGMT is a suicide DNA repair enzyme that directly reverses O6-alkylguanine lesions by stoichiometrically transferring the alkyl group to its active-site Cys145, after which the inactivated protein is polyubiquitinated and degraded by the proteasome [PMID:2405387, PMID:8573590]. Structural studies reveal that MGMT binds the DNA minor groove through a helix-turn-helix motif, flips the damaged nucleotide out of the duplex via Tyr114-assisted phosphate rotation, and executes methyl transfer at Cys145 [PMID:15221026]. MGMT transcription is controlled by BRD4-dependent promoter activity, a distal MKI67-proximal enhancer, p53/mSin3A/HDAC1-mediated repression, and Fstl1/DIP2A/HDAC2-regulated chromatin acetylation, while post-translationally NDRG1 stabilizes MGMT protein and PARP1 PARylates MGMT to enhance repair through BER–direct-repair crosstalk [PMID:36513631, PMID:30054476, PMID:20525765, PMID:30542120, PMID:24367102, PMID:36242092]. When MGMT is absent, unrepaired O6-methylguanine triggers MSH2/MSH6/MLH1/PMS2-dependent ATR-Chk1 checkpoint activation and apoptosis via ATM/ATR–p53/p73 signaling, and MGMT mRNA export is further enhanced under alkylation stress through CHK1-dependent DDX46 phosphorylation and LINC01956 structural remodeling [PMID:35388070, PMID:17485253, PMID:39356744].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Cloning of human MGMT established that O6-alkylguanine repair proceeds through a suicide mechanism in which the enzyme irreversibly transfers the alkyl group to an active-site cysteine, explaining the stoichiometric depletion of repair capacity in mammalian cells.\",\n      \"evidence\": \"Functional complementation cloning in E. coli ada− mutant with in vitro methyltransferase activity assay and Northern blot\",\n      \"pmids\": [\"2405387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-site cysteine not yet identified by mutagenesis\", \"No structural information on substrate recognition\", \"Post-translational fate of alkylated protein unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"The question of how inactivated MGMT is cleared was resolved by showing that alkylated MGMT is polyubiquitinated and degraded via the ATP-dependent proteasome pathway, establishing a complete single-use repair cycle.\",\n      \"evidence\": \"Co-IP with anti-ubiquitin antibodies, cell-free ubiquitination assay, and temperature-sensitive ubiquitin-activating enzyme mutant (ts85 cells)\",\n      \"pmids\": [\"8573590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for MGMT ubiquitination not identified\", \"Whether sumoylation or other PTMs modulate degradation kinetics\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Genetic epistasis experiments answered why MGMT loss is cytotoxic: unrepaired O6-methylguanine is processed by mismatch repair into a lethal signal, establishing the MGMT–MMR functional opposition that underlies alkylating-agent sensitivity.\",\n      \"evidence\": \"Cell viability and apoptosis assays in cells with modulated MGMT and MMR status; antisense and overexpression experiments\",\n      \"pmids\": [\"11554312\", \"13679151\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact nature of the MMR-generated lethal intermediate (futile cycling vs. strand break) not resolved\", \"Whether MMR-independent killing occurs for specific adduct types\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Crystal structures of MGMT bound to O6-methylguanine-containing DNA revealed the catalytic mechanism: minor-groove HTH binding, Tyr114-driven phosphate rotation to flip the damaged base, and direct alkyl transfer to Cys145, answering how a single protein accomplishes lesion recognition and repair in one step.\",\n      \"evidence\": \"X-ray crystallography of human MGMT–dsDNA complexes with substrate and crosslinked inhibitor; site-directed mutagenesis of Tyr114 and Cys145\",\n      \"pmids\": [\"15221026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of nucleotide flipping in solution not captured by crystal structures\", \"Structural basis for cooperative binding to DNA not fully resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The downstream signaling cascade following MGMT deficiency was mapped: unrepaired O6-methylguanine activates ATM/ATR–Chk1/Chk2–p53/p73 through MutSα-dependent MMR, engaging both death-receptor and mitochondrial apoptotic pathways, while O6-chloroethylguanine killing was shown to be MMR-independent.\",\n      \"evidence\": \"MGMT-modulated cell lines with epistasis across MMR-deficient lines; caspase activation and cytochrome c release assays\",\n      \"pmids\": [\"17485253\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of p53 vs. p73 in different cell types unclear\", \"Whether ATR-Chk1 signaling is the sole checkpoint engaged\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"NDRG1 was identified as a direct binding partner that stabilizes MGMT protein, revealing a post-translational mechanism by which the hypoxia–mTORC2–SGK1 axis sustains alkylating-agent resistance independently of MGMT transcription.\",\n      \"evidence\": \"Reciprocal Co-IP of NDRG1–MGMT; genetic knockdown/overexpression; glioma patient tissue and mouse xenograft validation\",\n      \"pmids\": [\"24367102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NDRG1–MGMT interaction unknown\", \"Whether NDRG1 shields specific ubiquitination sites not determined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Multi-layered transcriptional regulation of MGMT was established: a distal enhancer between MKI67 and MGMT drives resistance-associated upregulation, while the Fstl1/DIP2A/HDAC2-DMAP1 axis controls H3K9 acetylation at the MGMT promoter, answering how MGMT expression is reactivated in resistant tumors despite promoter methylation.\",\n      \"evidence\": \"CRISPR enhancer deletion and dCas9 activation with ATAC-seq/ChIP-seq (enhancer study); Co-IP plus ChIP for H3K9Ac and epistasis with DIP2A knockdown (Fstl1 study); PDX models\",\n      \"pmids\": [\"30054476\", \"30542120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors binding the MKI67-proximal enhancer not fully catalogued\", \"Whether enhancer activation is specific to recurrent GBM or a general mechanism\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The checkpoint consequence of MGMT loss was refined: ATR-Chk1 activation by temozolomide requires MSH2, MSH6, MLH1, and PMS2 but not MSH3, delineating the specific MMR components that transduce unrepaired O6-methylguanine into checkpoint signaling and revealing ATR inhibitor vulnerability in MGMT-deficient tumors.\",\n      \"evidence\": \"Isogenic shRNA knockdown panel of individual MMR genes in MGMT-methylated GBM cells; phospho-ATR/Chk1 immunoblotting; ATR inhibitor treatment in vitro and in xenografts\",\n      \"pmids\": [\"31273061\", \"35388070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ATR inhibitor sensitivity extends to all MGMT-deficient tumor types\", \"Role of secondary MMR-independent checkpoint pathways not excluded\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"BRD4 was shown to occupy the MGMT promoter and sustain Pol II–driven transcription, and PARP1 was found to PARylate MGMT in a DNA-independent manner enhancing its repair activity, revealing two previously unrecognized regulatory nodes—one transcriptional, one post-translational—that converge on MGMT output.\",\n      \"evidence\": \"ChIP for BRD4/Pol II with BET-inhibitor treatment and ectopic MGMT rescue (transcription); reciprocal Co-IP of PARP1–MGMT and in vitro PARylation plus repair activity assay (PTM)\",\n      \"pmids\": [\"36513631\", \"36242092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which PARylation sites on MGMT are functionally relevant not mapped\", \"Whether BRD4-dependent transcription operates at the distal enhancer as well as the core promoter\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A post-transcriptional resistance mechanism was uncovered: CHK1 phosphorylates DDX46, whose increased helicase activity remodels lncRNA LINC01956 to expose motifs that recruit MGMT mRNA for nuclear export, explaining how cytoplasmic MGMT protein rises during alkylation stress even in promoter-methylated tumors.\",\n      \"evidence\": \"RNA structural probing (SHAPE/DMS-MaPseq), RIP, ChIRP, phosphoproteomics of DDX46, CHK1 inhibitor rescue in PDX and tumor organoid models\",\n      \"pmids\": [\"39356744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LINC01956-mediated export applies to non-glioblastoma contexts\", \"Identity of the nuclear export receptor that recognizes remodeled LINC01956\", \"Whether other RNA helicases can substitute for DDX46\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the E3 ubiquitin ligase(s) targeting alkylated MGMT for degradation, the structural basis of the NDRG1–MGMT and PARP1–MGMT interactions, and whether the transcriptional activator function of MGMT at the DUB3 promoter represents a widespread non-canonical role or a context-specific phenomenon.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"E3 ligase for MGMT ubiquitination remains unidentified\", \"No co-crystal structure of MGMT with any of its regulatory partners\", \"Non-canonical transcription factor activity of MGMT at DUB3 awaits independent replication\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 15, 19]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 1, 3, 5, 6, 15]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [3, 4, 6, 14, 17]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [7, 10, 11, 16]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"NDRG1\",\n      \"PARP1\",\n      \"BRD4\",\n      \"DDX46\",\n      \"DIP2A\",\n      \"HDAC8\",\n      \"ADRM1\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}